MX347325B - Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos. - Google Patents

Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos.

Info

Publication number
MX347325B
MX347325B MX2009014052A MX2009014052A MX347325B MX 347325 B MX347325 B MX 347325B MX 2009014052 A MX2009014052 A MX 2009014052A MX 2009014052 A MX2009014052 A MX 2009014052A MX 347325 B MX347325 B MX 347325B
Authority
MX
Mexico
Prior art keywords
calcium channel
channel blockers
short acting
methods
relates
Prior art date
Application number
MX2009014052A
Other languages
English (en)
Other versions
MX2009014052A (es
Inventor
P Maguire Martin
Rioux Elise
j leighton Harry
Original Assignee
Milestone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40156562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347325(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milestone Pharmaceuticals Inc filed Critical Milestone Pharmaceuticals Inc
Publication of MX2009014052A publication Critical patent/MX2009014052A/es
Publication of MX347325B publication Critical patent/MX347325B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al el uso de una cantidad farmacéuticamente efectiva de un compuesto bloqueador de canal de calcio de corta acción para tratar condiciones isquémicas del corazón, arritmias cardiacas, crisis de hipertensión en un ambiente de sala de emergencias, hipertensión antes, durante y después de cirugía, fenómeno de no reflujo después de repercusión, y enfermedades asociadas con flujo sanguíneo muscular esquelético disminuido. La invención también se refiere a composiciones farmacéuticas formuladas para uso en tales métodos y a Kits para tales métodos.
MX2009014052A 2007-06-20 2008-06-19 Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos. MX347325B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93644007P 2007-06-20 2007-06-20
PCT/US2008/007665 WO2008156820A1 (en) 2007-06-20 2008-06-19 Short acting phenylalkylamine calcium channel blockers and uses thereof

Publications (2)

Publication Number Publication Date
MX2009014052A MX2009014052A (es) 2010-03-01
MX347325B true MX347325B (es) 2017-04-12

Family

ID=40156562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014052A MX347325B (es) 2007-06-20 2008-06-19 Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos.

Country Status (18)

Country Link
US (19) US20100190852A1 (es)
EP (1) EP2170050B1 (es)
JP (1) JP5421908B2 (es)
KR (1) KR101541557B1 (es)
CN (1) CN101754678B (es)
AU (1) AU2008266798B2 (es)
BR (1) BRPI0812919B8 (es)
CA (1) CA2693627C (es)
CY (1) CY1115619T1 (es)
DK (1) DK2170050T3 (es)
ES (1) ES2498047T3 (es)
HR (1) HRP20140801T1 (es)
MX (1) MX347325B (es)
NZ (1) NZ582033A (es)
PL (1) PL2170050T3 (es)
PT (1) PT2170050E (es)
SI (1) SI2170050T1 (es)
WO (1) WO2008156820A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2170050T1 (sl) 2007-06-20 2014-12-31 Milestone Pharmaceuticals Inc. Fenilalkilaminski blokatorji kalcijevih kanalov s kratkotrajnim delovanjem in njihova uporaba
KR101052620B1 (ko) * 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
KR101644286B1 (ko) * 2009-09-30 2016-08-10 마이크로도스 테라퓨특스, 인코포레이티드 레이노 증후군의 치료를 위한 방법들 및 조성물들
WO2015073919A1 (en) * 2013-11-14 2015-05-21 University Medical Pharmaceuticals Corporation Microneedles for therapeutic agent delivery with improved mechanical properties
JP6785792B2 (ja) * 2015-04-14 2020-11-18 マイルストーン ファーマシューティカルズ インコーポレーテッド 短時間作用性フェニルアルキルアミンカルシウムチャネル遮断薬の高水溶性塩及びその使用
US12257224B2 (en) 2021-07-15 2025-03-25 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
IT202400008038A1 (it) 2024-04-10 2025-10-10 Dipharma Francis Srl Metodo di preparazione di un farmaco usato per la tachicardia parossistica sopraventricolare
WO2025229679A1 (en) * 2024-04-30 2025-11-06 Cipla Limited Process for synthesis of etripamil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3957845A (en) * 1962-04-27 1976-05-18 Knoll A.G. Chemische Fabriken Trifluoromethyl-substituted phenyl acetonitriles
DE1493904A1 (de) * 1965-07-31 1969-06-19 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE2059923C3 (de) * 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
JPS5118940B2 (es) * 1971-12-25 1976-06-14
DE2631222C3 (de) * 1976-07-12 1979-01-04 Knoll Ag, 6700 Ludwigshafen Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE3144150A1 (de) * 1981-04-10 1982-12-09 Basf Ag, 6700 Ludwigshafen (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
US4833162A (en) * 1988-02-03 1989-05-23 American Cyanamid Company Substituted benzeneacetonitriles and their use as calcium channel blockers
US5162569A (en) 1989-12-21 1992-11-10 G. D. Searle & Co. Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
IE64870B1 (en) 1989-12-21 1995-09-20 Searle & Co Methods of using 2-isopropyl-2-phenylaminovaleronitriles immunosuppressants and vasodilators
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5451604A (en) * 1993-07-26 1995-09-19 G. D. Searle & Co. Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
US5910601A (en) * 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5859279A (en) 1996-09-10 1999-01-12 Darwin Discovery Limited Compound and process
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
GB2435824A (en) 2006-03-09 2007-09-12 Esteve Labor Dr Use of nitrile compounds in the treatment of food related and other disorders
SI2170050T1 (sl) 2007-06-20 2014-12-31 Milestone Pharmaceuticals Inc. Fenilalkilaminski blokatorji kalcijevih kanalov s kratkotrajnim delovanjem in njihova uporaba

Also Published As

Publication number Publication date
PL2170050T3 (pl) 2014-12-31
US10010523B2 (en) 2018-07-03
US9463179B2 (en) 2016-10-11
US20140296335A1 (en) 2014-10-02
HRP20140801T1 (hr) 2014-11-21
US20210059972A1 (en) 2021-03-04
US10010524B2 (en) 2018-07-03
BRPI0812919A2 (pt) 2014-10-07
US20200230097A1 (en) 2020-07-23
US9737503B2 (en) 2017-08-22
BRPI0812919B8 (pt) 2021-05-25
EP2170050B1 (en) 2014-06-18
KR101541557B1 (ko) 2015-08-03
EP2170050A1 (en) 2010-04-07
AU2008266798A1 (en) 2008-12-24
US9227918B2 (en) 2016-01-05
JP2010530429A (ja) 2010-09-09
ES2498047T3 (es) 2014-09-24
CY1115619T1 (el) 2017-01-04
US20250195462A1 (en) 2025-06-19
US20220142963A1 (en) 2022-05-12
CA2693627A1 (en) 2008-12-24
CN101754678B (zh) 2014-04-16
US20100190852A1 (en) 2010-07-29
KR20100043175A (ko) 2010-04-28
CA2693627C (en) 2016-01-12
US20180280339A1 (en) 2018-10-04
US20210315855A1 (en) 2021-10-14
CN101754678A (zh) 2010-06-23
US20170312242A1 (en) 2017-11-02
US20240115543A1 (en) 2024-04-11
US10010522B2 (en) 2018-07-03
US20160374982A1 (en) 2016-12-29
US20170312241A1 (en) 2017-11-02
JP5421908B2 (ja) 2014-02-19
AU2008266798B2 (en) 2014-07-17
WO2008156820A1 (en) 2008-12-24
MX2009014052A (es) 2010-03-01
US20170312243A1 (en) 2017-11-02
NZ582033A (en) 2012-07-27
US20240366552A1 (en) 2024-11-07
EP2170050A4 (en) 2010-11-24
US20160074354A1 (en) 2016-03-17
HK1140913A1 (en) 2010-10-29
PT2170050E (pt) 2014-09-04
BRPI0812919B1 (pt) 2019-01-29
US20190142781A1 (en) 2019-05-16
SI2170050T1 (sl) 2014-12-31
DK2170050T3 (da) 2014-09-29
US20230255923A1 (en) 2023-08-17
US20260174722A1 (en) 2026-06-25
US20190380993A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2009014052A (es) Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos.
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
EP2422819A3 (en) Compositions and their uses directed to Huntingtin
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ME02450B (me) POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
TW200621765A (en) Substituted phenylaminothiazoles and their use
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
RU2011129830A (ru) Производные 1-амино-алкилциклогексана для лечения заболеваний, опосредованных тучными клетками
PH12022553376A1 (en) Acalabrutinib maleate dosage forms
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
UA99638C2 (ru) Оксазолидиноны для лечения и/или профилактики сердечной недостаточности
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration